BioSpace News Archive

Business

Medigene Collaborates With RXi Pharma to Further Sharpen its Therapeutic T cells

The preclinical research program will examine the applicability of RXi’s sd-rxRNA technology to be integrated into Medigene’s process to produce receptor-modified T cells with the ultimate goal to further improve Medigene’s T cell therapies for the treatment of cancer patients.

December 11, 2017
·
6 min read
Biotech Beach

Regen BioPharma Files Additional Composition of Matter Patent Application on NR2F6-Modulating Small Molecules

Regen BioPharma today announced filing a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that activate and inhibit NR2F6.

December 11, 2017
·
2 min read
Drug Development

Betalutin Shows Strong Clinical Profile in Relapsed/Refractory Indolent NHL and Follicular Lymphoma

The updated data continue to highlight Betalutin’s strong clinical profile as a single agent for treatment of R/R iNHL, and particularly of 3L FL.

December 11, 2017
·
6 min read
Drug Development

Genentech’s Tecentriq Cocktail Meets Co-Primary Goal in Phase III Study

TECENTRIQ and Avastin showed improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1.

December 11, 2017
·
16 min read
Drug Development

ADC Therapeutics Announces Interim Phase I Data From Its Novel Antibody-Drug Conjugate ADCT-301

ADC Therapeutics announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or “Cami-T”) in important subtypes of lymphoma and leukemia.

December 11, 2017
·
6 min read
Business

BD Establishes Product Security Partnership Program to Enhance Cybersecurity of Medical Technology

BD today announced it has established a Product Security Partnership Program that emphasizes collaboration across the health care industry to enhance cybersecurity of medical technology and devices.

December 11, 2017
·
5 min read
Policy

Prometic’s PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From the UK MHRA in the Treatment of Idiopathic Pulmonary Fibrosis

ProMetic Life Sciences announced today that its orally-active drug candidate, PBI-4050, has been issued a Promising Innovative Medicine designation by the UK MHRA as add-on treatment to nintedanib in patients with idiopathic pulmonary fibrosis.

December 11, 2017
·
5 min read
Genetown

Pillar Biosciences Announces Issuance of China and U.S. Patents Covering SLIMamp Technology

The SIPO of the People’s Republic of China issued patent ZL201680001111.1 with a duration of 20 years.

December 11, 2017
·
2 min read
Drug Development

Sophiris Bio Announces Complete Enrollment in Phase IIb Topsalysin Study of Localized Prostate Cancer

Sophiris Bio today announced that it has completed enrollment in its Phase 2b study to evaluate the safety and tolerability of topsalysin in treating men with clinically significant localized prostate cancer.

December 11, 2017
·
6 min read